VHCP Management II as of March 31, 2016
Portfolio Holdings for VHCP Management II
VHCP Management II holds 22 positions in its portfolio as reported in the March 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 16.1 | $25M | 1.0M | 23.66 | |
| Edge Therapeutics | 11.6 | $18M | 1.9M | 9.15 | |
| Ascendis Pharma A S (ASND) | 8.8 | $13M | 721k | 18.55 | |
| BioCryst Pharmaceuticals (BCRX) | 8.7 | $13M | 4.7M | 2.83 | |
| Dbv Technologies | 8.0 | $12M | 214k | 56.92 | |
| Regenxbio Inc equity us cm (RGNX) | 7.3 | $11M | 1.0M | 10.80 | |
| Heron Therapeutics (HRTX) | 5.1 | $7.7M | 406k | 18.99 | |
| Cytomx Therapeutics (CTMX) | 4.9 | $7.4M | 578k | 12.86 | |
| Coherus Biosciences (CHRS) | 3.6 | $5.5M | 259k | 21.23 | |
| Akari Therapeutics | 3.4 | $5.2M | 370k | 14.00 | |
| Axovant Sciences | 3.2 | $4.9M | 430k | 11.48 | |
| Alcobra | 2.8 | $4.3M | 1.1M | 3.79 | |
| Lipocine | 2.8 | $4.3M | 420k | 10.15 | |
| ARCA biopharma | 2.5 | $3.7M | 1.1M | 3.47 | |
| Beigene (BGNE) | 2.3 | $3.5M | 119k | 29.31 | |
| Cynapsus Therapeutics | 2.0 | $3.1M | 253k | 12.13 | |
| Ocera Therapeutics | 1.8 | $2.8M | 948k | 2.94 | |
| Global Blood Therapeutics In | 1.8 | $2.7M | 170k | 15.86 | |
| D Stemline Therapeutics | 1.0 | $1.5M | 316k | 4.66 | |
| Avalanche Biotechnologies In | 0.9 | $1.4M | 280k | 5.17 | |
| Zafgen | 0.6 | $945k | 142k | 6.68 | |
| Pronai Therapeutics | 0.6 | $882k | 131k | 6.74 |
